DRUG
desmopressin melt form 120 μg
Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.
Uroflowmetry and Nocturnal Enuresis
Status
Active, not recruiting
Phase
Not applicable
Enrollment
100
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis.
Full detailed description
A total of approximately 100 patients with enuresis will be evaluated retrospectively. Uroflowmetry parameters of these patients will be evaluated. For this purpose, patients will be divided to mainly three groups according to the treatment choices.
Interventions
Treatment arms and agents.
DRUG
Desmopressin lyophilisate (Melt)
Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.
DRUG
Propiverine tablet
Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg
Timeline
From registration to results.
First posted
Jun 19, 2025
Study start
Aug 20, 2022
Primary completion
Sep 1, 2024
Study completion
Dec 30, 2025
Results posted
Not reported
Registry updated
Jun 24, 2025
Outcomes
What the study measures.
Primary outcomes
Number of days without bedwetting
Time frame · 1 month
Achievement of bedwetting in one or less night of a month
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 5 Years
- Maximum age
- 17 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Presence of enuresis nocturna * Patients who have uroflowmetry test Exclusion Criteria: * Presence of lower urinary tract symptoms * Presence of anatomical or neurological problems * Patients with missing data
Study locations
1 registered sites.
Turkey (Türkiye). Showing up to 24 locations stored in the fast local snapshot.
Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital
Istanbul, Kadikoy, Turkey (Türkiye)
Publications
Results and literature.
Related trials
More studies on Desmopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.